About Astellas

Turn innovative science into VALUE for patients

Since Astellas was established in 2005, the company has strived to continue to create innovation and deliver innovative medical solutions that meet the needs of patients. Going forward, we are committed to achieving our vision of tuning innovative science into VALUE for patients.
In the future as well, Astellas aims to stand on the forefront of healthcare change to turn innovative science into VALUE for patients and will continually strive to fulfill the expectations of our stakeholders and society.

At a glance

At a glance

Global business expansion

Astellas’ overseas sales ratio is around 80%. We currently sell products in about 70 countries around the world, including developing countries. 

Revenue by Region



Sales of major products

In addition to its main products, XTANDI® for the treatment of prostate cancer and Betanis/Myrbetriq/BETMIGA for the treatment of overactive bladder (OAB), Astellas is working to develop and maximize the value of new products which will drive our growth, such as XOSPATA® for the treatment of acute myeloid leukemia, PADCEV® for the treatment of urothelial cancer, and Evrenzo® for the treatment of anemia associated with chronic kidney disease, launched during the period of Corporate Strategic Plan 2018.


Consolidated Revenue



Astellas recognizes its contribution to environmental and social sustainability is essential for our business continuity. We aim to enhance our corporate value by engaging in Value Creation and Value Protection, while taking environmental, social and governance (ESG) issues into consideration.



External evaluation

Astellas’ Sustainability initiatives have been receiving positive external evaluations.  

FTSE Blossom Japan
placeholder image